We’re the most valuable ally on your path to investment success


Essential for market commercialization and validating VCs investment

Venture Capitals (VCs) are the lifeblood of younger established Pharma and smaller emerging Biotech and are involved with discussing and reviewing the pertinent development data expectations. Enkrisi illustrates the necessary regulatory information to assure that informed decisions are made regarding the potential in/out-licensing of a development compound. Due diligence is a vital activity in the acquisition or the in/out-licensing of pharmaceuticals for market commercialization. Pharmaceutical product due diligence is a detailed investigation of the CMC information. The investigation assures that a given compound will meet the requisite technical and quality elements to allow for the successful commercialization of the drug product. Enkrisi provides an overview of the essential CMC information reviewed in the drug product due diligence activities. This follows strategic CMC regulatory expectations based on development, technology transfer, and commercialization expectations, as well as the areas of registration, approval, and regulation of medicines by government agencies to advise organizations on CMC aspects of regulatory submissions, development, and implementation of CMC regulatory strategy and identifying and assessing regulatory risks.

We assist VCs in overcoming these challenges.

Our CMC regulatory service offering is tailored to support Venture Capital (VC) groups who are in-licensing or funding a drug sponsor running clinical trials. We understand the unique challenges VC groups face in evaluating the drug development process and the importance of ensuring compliance with regulatory requirements to maximize success. To help VCs ensure the value of their investment, we offer the following services:


We are committed to providing the highest level of support to help VC groups navigate the complex regulatory landscape and ensure successful investment outcomes. By partnering with us, VC groups can have peace of mind knowing that their investment is being managed with the highest level of regulatory compliance and technical expertise and that potential risks are identified and mitigated early in the drug development process.

We help you with

We’re more than a team of experts, we’re your partners

This Consulting firm is investing now to build new models and technology that allow us to offer promising AI-based solutions. An example of how disruptive AI can be to the industry is the introduction of Robo-advisors. Financial consultants providing asset management services are witnessing their functions quickly become automated. (Think Regulatory Robo Advisors)

The firms that incorporate AI into consulting projects and train consultants to utilize that technology (or offer the technology directly to the sponsor client) will gain a competitive advantage in the AI age. The firms preparing to bridge the AI-based tools created by tech firms and the real strategic challenges faced by prospective clients are also likely to find themselves a sustainable niche in the new business environment. 


Your success,

our pride

Enkrisi’s Regulatory Strategy Team: Highly Skilled and Effective in the Pharmaceutical Industry

As someone who has worked in the pharmaceutical industry for several years, I can say without hesitation that Enkrisi’s Regulatory strategy team is top-notch. Their team of experts is highly skilled at navigating the complex regulatory landscape, and they are always on top of the latest developments in the industry. I highly recommend their services to anyone looking to bring a new drug to market. Enkrisi’s Regulatory Consultants have a strong history of effective communication. They can author critical messages supported by scientifically-cohesive narratives, reports, and data summaries for your investigational and marketing submission documents.

Lisa D

VP, Regulatory Affairs and Quality Assurance

Enkrisi’s Quality and Expertise Critical to Drug Sponsor Success

Since transitioning to a drug sponsor role, I have continued to rely on Enkrisi for their guidance and assistance in ensuring our drug product meets regulatory standards and is ready for commercial distribution. Your team’s attention to detail and commitment to quality have been crucial to our success. Enkrisi’s experienced contract regulatory writers can provide Common Technical Document (CTD) content, FDA Briefing Books, meeting minutes, slides, and more to help you meet or beat every deadline, challenge and improve document quality, and become someone you can unquestionably rely on.

Lynn G

SVP Regulatory Affairs

Enkrisi: Top-Tier Drug Development Support for Due Diligence and Licensing Deals

Enkrisi’s drug development support services are among the best I have ever encountered for due diligence and licensing deals. Their team of experts is highly knowledgeable about all aspects of CMC operations management, and they are always willing to provide guidance and support to help their clients succeed. They are genuinely passionate about what they do and are committed to helping their clients bring new, innovative drugs to market.

Brian S

Operating Partner - Life Sciences

Enkrisi: Exceptional Drug Development Support from Research to Commercial Distribution

Enkrisi’s drug development support is truly exceptional. From the earliest stages of research to the final phases of clinical trials, their team is there every step of the way, providing guidance and support to help ensure success. Their expertise in CMC operations management is particularly impressive, and they are always willing to go above and beyond to help their clients achieve their goals. If you are developing a pharmaceutical drug product for commercial distribution, seeking expert assistance with CMC regulatory work from Enkrisi can help you manage and lower regulatory risk and avoid regulatory delay.

Jamie D

Director of CMC

The latest in biotech for your ears

The VirtualPharm Podcast is an audio series that covers topics related to compliance and regulatory affairs in the Lifesciences industry. Each episode, hosted by an expert in the topic with decades of experience, offers listeners detailed insight into the changing regulatory environment.

The latest in biotech for your eyes

The PathFinder focuses on relevant topics such as regulatory developments, compliance trends, legal updates, enforcement actions, industry insights, and best practices. Articles are written by experts in the field to ensure accuracy and help sponsor companies stay informed about changes in their regulatory environment.

Lets discuss your product